Kidney Transplant Clinical Trials

Clinical trials related to Kidney Transplant Procedure

China Glomerulonephritis Kidney Transplant Recipient Cohort: A Prospective Multicenter Observational Study

Status: Recruiting
Location: See all (9) locations...
Study Type: Observational
SUMMARY

This is a prospective observational study aimed at establishing a prospective observational cohort of patients with a confirmed diagnosis of glomerulonephritis (GN) before kidney transplantation in China. Information will be collected on the epidemiology of GN recurrence after kidney transplantation, as well as the outcomes and treatment of the primary disease following kidney transplantation, to provide evidence for subsequent clinical studies, drug development, and translational research. Approximately 300 patients with a confirmed diagnosis of GN before transplantation will be prospectively enrolled. Clinical data will be collected during screening, kidney transplantation, and a 3-year post-transplant follow-up. The frequency of follow-up visits is every 3 months in the 1st year after transplantation, and every 6 months during the 2nd to 3rd years, with a total of 8 follow-up visits. The study will be conducted at 10 sites across China.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years.

• Diagnosed with primary GN based on clinical guidelines and/or expert consensus

• Successfully matching completed and confirmed to be scheduled for kidney transplantation.

Locations
Other Locations
China
Research Site
NOT_YET_RECRUITING
Beijing
Research Site
NOT_YET_RECRUITING
Guangzhou
Research Site
RECRUITING
Nanning
Research Site
TERMINATED
Shanghai
Research Site
NOT_YET_RECRUITING
Taiyuan
Research Cite
NOT_YET_RECRUITING
Tianjin
Research Site
NOT_YET_RECRUITING
Wuhan
Research Site
NOT_YET_RECRUITING
Yantai
Research Site
NOT_YET_RECRUITING
Zhengzhou
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2026-10-01
Estimated Completion Date: 2030-08-29
Participants
Target number of participants: 300
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca

This content was sourced from clinicaltrials.gov